Neutralizing Antibody Specific for Mouse (VEGFR)-2 Reduces Joint Damage in Chronic Inflammatory Arthritis

Brief Description
Recent studies demonstrated that angiogenesis plays a role in the pathogenesis of inflammatory-erosive arthritis such as rheumatoid arthritis (RA).  Angiogenesis is regulated by multiple factors and signal pathways. VEGF-A, the most studied angiogenic factor,  works through VEGFR1 and VEGFR2-mediated pathways in blood endothelial cells. VEGFR1 inhibition has been shown to reduce joint lesions in animal models of RA, but the role of VEGFR2-mediated events in RA pathology has not been fully elucidated.  In this invention, Dr Xing examined the effect of VEGFR2 neutralizing antibody on joint lesions in TNF induced arthritis.  This is a well characterized mouse model of RA.  They used MRI images to monitor the changes of ankle synovial volume before and after 8-week treatment of the same animals.  The data suggest that this VEGFR2-antibody may be useful to treat joint lesion of RA or other forms of inflammatory-erosive arthritis.
Patent Information:
Title Country Patent No. Issued Date
Methods and Compositions for Treating Inflammatory Conditions United States 8,580,755 11/12/2013
For Information, Contact:
Weimin Kaufman
Licensing Manager
University of Rochester
Lianping Xing
Brendan Boyce
Edward Schwarz